Dysregulation of dopamine metabolism in children with spinal muscular atrophy type 1

Clicks: 4
ID: 337778
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #188 of 194 articles by views in Brain communications

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 194 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Spinal muscular atrophy (SMA) is a severe neuromuscular disorder caused by reduced expression of the survival motor neuron (SMN) protein. In addition to affecting motor neuron survival, SMN deficiency impacts multisystem physiology and neurotransmission. Dopaminergic dysfunction has been reported in mouse models of SMA, leading to postural and locomotor impairments that improve following treatment with levodopa and benserazide, which increase central dopamine availability. However, whether altered dopamine metabolism contributes to clinical symptoms in SMA patients remains unclear. To investigate this issue, we conducted a real-world observational study involving pediatric patients with SMA type 1 (SMA1), SMA2, and SMA3, and healthy controls. We quantified the main dopamine-related catabolites – 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) – in cerebrospinal fluid samples collected at baseline and after five intrathecal doses of Nusinersen, an SMN-enhancing therapy. No significant differences were observed in DOPAC and HVA levels across SMA types and controls or following treatment, and no association emerged with SMN2 copy number. In contrast, lower baseline DOPAC levels were detected in SMA1 patients requiring gastrostomy or tracheostomy, and were associated with reduced improvement following Nusinersen, as measured by changes in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders scores. Additional high-performance liquid chromatography analyses performed in an independent study cohort revealed significantly lower serum HVA levels in SMA1 patients compared to controls. In conclusion, our exploratory study suggests that altered dopaminergic metabolism is associated with greater disease severity and poorer motor outcomes following treatment, supporting an involvement of dopamine neurotransmission in clinical heterogeneity in SMA.
Reference Key
openalex_W7224325101 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tommaso Nuzzo, Barbara Risi, Valentina Bassareo, Adele D’Amico, Alberto Imarisio, Antonella Longo, Manolo Carta, Chiara Panicucci, Claudio Bruno, Enza Maria Valente, Massimiliano Filosto, Enrico Bertini, Francesco Errico, Alessandro Usiello
Journal Brain communications
Year 2026
DOI
10.1093/braincomms/fcag402
URL
https://doi.org/10.1093/braincomms/fcag402
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.